SELECT Pooled Analysis: Incidence and Risk Factors for VTE in Patients With RA Treated With Upadacitinib

November 5-9, 2020; Virtual Meeting
Pooled analysis of 5 phase III trials in RA suggests that history of VTE and higher BMI were risk factors for VTE in those receiving upadacitinib.
Format: Microsoft PowerPoint (.ppt)
File Size: 203 KB
Released: November 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Sanofi Genzyme Corporation

Related Content

Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.

Released: December 23, 2020

Safety: Frequently asked questions from the CCO Webinar series, “ A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis”

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: December 18, 2020

From ACR/ARP 2020: expert-authored commentary on evaluating RA and the utility of telemedicine, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD William F. C. Rigby, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue